Co-localization of CD169+ macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression

ABSTRACT Breast cancer is the most common form of cancer in women worldwide. Although the survival among breast cancer patients has improved, there is still a large group of patients with dismal prognosis. One of the most important prognostic factors for poor prognosis is lymph node metastasis. Increasing knowledge concerning the lymph nodes of breast cancer patients indicates that they are affected by the primary tumor. In this study we show that presence of CD169+ subcapsular sinus macrophages in contact with lymph node metastases in breast cancer patients, is related to better prognosis after adjuvant tamoxifen treatment, but only in patients with PDL1+ primary tumors. This is in contrast to the prognostic effect of CD169+ primary tumor-associated macrophages (TAMs). We further show that CD169+ macrophages were spatially associated with expression of PDL1 on nearby cells, both in primary tumors and metastatic lymph node, although PDL1 expression in metastatic lymph node as such did not have further prognostic impact. Our data suggest that CD169+ resident lymph node macrophages have a unique function in targeting immune responses against breast cancer and should be further investigated in detail.

[1]  K. Leandersson,et al.  The Generation and Identity of Human Myeloid-Derived Suppressor Cells , 2020, Frontiers in Oncology.

[2]  Yueping Liu,et al.  PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. , 2019, Pathology, research and practice.

[3]  Masato Tanaka,et al.  Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages. , 2019, International immunopharmacology.

[4]  W. Gu,et al.  PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition , 2019, Front. Immunol..

[5]  P. Spellman,et al.  Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets , 2019, Cancer cell.

[6]  S. Liao,et al.  Lymph Node Subcapsular Sinus Macrophages as the Frontline of Lymphatic Immune Defense , 2019, Front. Immunol..

[7]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[8]  E. Winer,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Masato Tanaka,et al.  CD169 macrophages regulate immune responses toward particulate materials in the circulating fluid. , 2018, Journal of biochemistry.

[10]  T. Kamba,et al.  CD169‐positive sinus macrophages in the lymph nodes determine bladder cancer prognosis , 2018, Cancer science.

[11]  T. Padera,et al.  Growth and Immune Evasion of Lymph Node Metastasis , 2018, Front. Oncol..

[12]  B. Ljungberg,et al.  Reduced number of CD169+ macrophages in pre‐metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients , 2017, The Prostate.

[13]  H. Iwase,et al.  The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer , 2016, PloS one.

[14]  S. Scheu,et al.  CD169+ macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection , 2016, Cell Death & Disease.

[15]  H. Katabuchi,et al.  Prognostic significance of CD169‐positive lymph node sinus macrophages in patients with endometrial carcinoma , 2016, Cancer science.

[16]  J. Sleeman.  The lymph node pre-metastatic niche , 2015, Journal of Molecular Medicine.

[17]  G. Kenter,et al.  Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area , 2015, Oncotarget.

[18]  L. Saal,et al.  Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer , 2015, Breast Cancer Research.

[19]  R. Kiessling,et al.  Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. , 2015, Trends in molecular medicine.

[20]  A. Mansfield,et al.  Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma , 2015, Oncoimmunology.

[21]  F. Bertucci,et al.  Prognostic and predictive value of PDL1 expression in breast cancer , 2014, Oncotarget.

[22]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[23]  G. Kenter,et al.  High and Interrelated Rates of PD-L1+CD14+ Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer , 2014, Cancer Immunology Research.

[24]  Xiumin Wang,et al.  PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients , 2014, Cancer Immunology, Immunotherapy.

[25]  Paolo Serafini,et al.  Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly , 2013, Immunologic research.

[26]  D. Chen,et al.  Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients , 2013, Journal of Translational Medicine.

[27]  H. Baba,et al.  CD169‐positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma , 2013, Cancer science.

[28]  W. Gillanders,et al.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer , 2013, Breast Cancer Research and Treatment.

[29]  J. Taube,et al.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.

[30]  M. Fernö,et al.  The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer , 2013, SpringerPlus.

[31]  Y. Lévy,et al.  Subcapsular sinus macrophages promote NK cell accumulation and activation in response to lymph-borne viral particles. , 2012, Blood.

[32]  Karin Jirström,et al.  The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients , 2012, BMC Cancer.

[33]  S. Gordon,et al.  CD169+ macrophages at the crossroads of antigen presentation. , 2012, Trends in immunology.

[34]  P. De Baetselier,et al.  Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. , 2011, The International journal of developmental biology.

[35]  P. Murray.  Faculty Opinions recommendation of CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. , 2011 .

[36]  Yasunobu Miyake,et al.  CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. , 2011, Immunity.

[37]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[38]  S. Gordon,et al.  Antigen Presentation the Macrophage Way , 2007, Cell.

[39]  L. Saal,et al.  Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma , 2007, Clinical Cancer Research.

[40]  Susan Holmes,et al.  Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer , 2005, PLoS medicine.

[41]  Mårten Fernö,et al.  Comparison of Immunohistochemical and Biochemical Assay of Steroid Receptors in Primary Breast Cancer Clinical Associations and Reasons for Discrepancies , 2003, Acta oncologica.

[42]  P. Crocker,et al.  Sialoadhesin-positive host macrophages play an essential role in graft-versus-leukemia reactivity in mice. , 1999, Blood.

[43]  R. Nanda,et al.  Immune Checkpoint Blockade for Breast Cancer. , 2018, Cancer treatment and research.

[44]  Christopher D. Chambers,et al.  Redefine statistical significance , 2017, Nature Human Behaviour.

[45]  Mårten Fernö,et al.  Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. , 2005, European journal of cancer.

[46]  D. Machin,et al.  Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. , 1997, Journal of the National Cancer Institute.